Cover Image
市場調查報告書

Celator Pharmaceuticals, Inc.:產品平台分析

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226257
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Celator Pharmaceuticals, Inc.:產品平台分析 Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 40 Pages
簡介

Celator Pharmaceuticals, Inc.是開發並銷售癌症治療藥的製藥企業。

本報告提供Celator Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Celator Pharmaceuticals, Inc.的基本資料

Celator Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Celator Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Celator Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Celator Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Celator Pharmaceuticals, Inc.:藥物簡介

  • (cytarabine hydrochloride + daunorubicin hydrochloride)
  • (irinotecan hydrochloride + floxuridine)
  • (irinotecan hydrochloride + cisplatin)
  • CPX-8
  • Small Molecule 1 for oncology
  • Small Molecules to Inhibit HDAC and DNA Methyltransferase for Oncology
  • Small Molecules to Inhibit Tubulin for Oncology

Celator Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Celator Pharmaceuticals, Inc.:最近的開發平台趨勢

Celator Pharmaceuticals, Inc.:暫停中的計劃

Celator Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07455CDB

Summary

Global Markets Direct's, 'Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Celator Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celator Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celator Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celator Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celator Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Celator Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celator Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celator Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celator Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celator Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celator Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celator Pharmaceuticals, Inc. Snapshot
    • Celator Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Celator Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Celator Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Celator Pharmaceuticals, Inc. - Pipeline Products Glance
    • Celator Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Celator Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Celator Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Celator Pharmaceuticals, Inc. - Drug Profiles
    • (cytarabine hydrochloride + daunorubicin hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (irinotecan hydrochloride + floxuridine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (irinotecan hydrochloride + cisplatin)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CPX-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC and DNA Methyltransferase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celator Pharmaceuticals, Inc. - Pipeline Analysis
    • Celator Pharmaceuticals, Inc. - Pipeline Products by Target
    • Celator Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Celator Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Celator Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Celator Pharmaceuticals, Inc. - Dormant Projects
  • Celator Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celator Pharmaceuticals, Inc., Key Information
  • Celator Pharmaceuticals, Inc., Key Facts
  • Celator Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Celator Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Celator Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Celator Pharmaceuticals, Inc. - Phase III, 2015
  • Celator Pharmaceuticals, Inc. - Phase II, 2015
  • Celator Pharmaceuticals, Inc. - Phase I, 2015
  • Celator Pharmaceuticals, Inc. - Preclinical, 2015
  • Celator Pharmaceuticals, Inc. - Discovery, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Celator Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Celator Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Celator Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Celator Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Celator Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Celator Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top